×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:BIIB

Biogen Price Target, Predictions & Analyst Ratings

$211.93
+0.55 (+0.26%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$207.19
$212.71
50-Day Range
$187.54
$223.02
52-Week Range
$187.16
$372.11
Volume
2.95 million shs
Average Volume
1.26 million shs
Market Capitalization
$31.04 billion
P/E Ratio
21.69
Dividend Yield
N/A
Price Target
$261.99

Biogen (NASDAQ:BIIB) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 27 Analyst Ratings

Consensus Analyst Price Target

$261.99
23.62% Upside
High Price Target$400.00
Average Price Target$261.99
Low Price Target$185.00
TypeCurrent
6/27/21 to 6/27/22
1 Month Ago
5/28/21 to 5/28/22
3 Months Ago
3/29/21 to 3/29/22
1 Year Ago
6/27/20 to 6/27/21
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
16 Buy rating(s)
15 Buy rating(s)
17 Buy rating(s)
Hold
13 Hold rating(s)
16 Hold rating(s)
17 Hold rating(s)
13 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$261.99$275.47$280.99$385.81
Predicted Upside23.62% Upside14.15% Upside15.99% Upside11.22% Upside
Get Biogen Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.


BIIB Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BIIB Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Biogen Stock vs. The Competition

TypeBiogenMedical CompaniesS&P 500
Consensus Rating Score
2.52
2.71
2.52
Consensus RatingModerate BuyBuyBuy
Predicted Upside23.62% Upside439.12% Upside29.94% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1692
73.85%
Underperform Votes
599
26.15%
Avg. Outperform Votes
170
66.93%
Avg. Underperform Votes
84
33.07%
Avg. Outperform Votes
839
69.11%
Avg. Underperform Votes
375
30.89%

Historical Biogen Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/4/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jay Olson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Target$240.00 ➝ $225.00+9.38%
5/4/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$219.00 ➝ $210.00+2.09%
4/28/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
4/21/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$300.00 ➝ $270.00+21.45%
4/18/2022Wells Fargo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$235.00 ➝ $265.00+24.68%
4/12/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$330.00 ➝ $283.00+34.37%
4/8/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ami Fadia
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$290.00 ➝ $262.00+23.80%
3/28/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Geoff Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral$230.00 ➝ $225.00+6.65%
3/8/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Paul Matteis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$304.00 ➝ $223.00+8.37%
3/3/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian Abrahams
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Outperform$227.00 ➝ $248.00+19.35%
2/7/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sumant Kulkarni
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$335.00 ➝ $305.00+38.83%
2/4/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$375.00 ➝ $285.00+31.25%
2/4/2022Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetPeer Perform$244.00 ➝ $217.00-1.44%
2/4/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian Skorney
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral$258.00 ➝ $224.00+1.74%
2/4/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$260.00 ➝ $238.00+8.10%
1/18/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Fein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$452.00 ➝ $270.00+12.83%
1/13/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$290.00 ➝ $202.00-10.36%
1/12/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Salim Syed
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral$270.00 ➝ $207.00-6.75%
1/12/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$362.00 ➝ $216.00-10.57%
1/10/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robyn Karnauskas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$502.00 ➝ $343.00+47.00%
1/3/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$390.00 ➝ $335.00+37.22%
12/21/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$324.00 ➝ $276.00+18.23%
12/6/2021The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$271.00+21.03%
10/28/2021Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Alethia Young
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral$316.00 ➝ $259.00-0.37%
10/18/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Yee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
7/19/2021Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set TargetBuy$324.62
6/11/2021Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$500.00+20.57%
6/8/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/8/2021Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Neutral
6/8/2021Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Neutral$415.00+4.84%
6/7/2021Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform
2/5/2021DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$264.00-1.27%
2/4/2021Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$388.00 ➝ $350.00+33.00%
7/8/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robyn Karnauskas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$330.00+17.78%
2/7/2020Nomura Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$320.00 ➝ $392.00+16.24%
11/1/2019Standpoint Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
7/26/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
(Data available from 6/27/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Biogen Price Target - Frequently Asked Questions

What is Biogen's consensus rating and price target?

According to the issued ratings of 27 analysts in the last year, the consensus rating for Biogen stock is Moderate Buy based on the current 13 hold ratings and 14 buy ratings for BIIB. The average twelve-month price prediction for Biogen is $261.99 with a high price target of $400.00 and a low price target of $185.00. Learn more on BIIB's analyst rating history.

Do Wall Street analysts like Biogen more than its competitors?

Analysts like Biogen stock less than the stock of other Medical companies. The consensus rating for Biogen is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how BIIB compares to other companies.

Do MarketBeat users like Biogen more than its competitors?

MarketBeat users like Biogen stock more than the stock of other Medical companies. 73.85% of MarketBeat users gave Biogen an outperform vote while medical companies recieve an average of 66.93% outperform votes by MarketBeat users.

Is Biogen being upgraded by Wall Street analysts?

Over the previous 90 days, Biogen's stock had 1 upgrade by analysts.

Does Biogen's stock price have much upside?

According to analysts, Biogen's stock has a predicted upside of 14.55% based on their 12-month price targets.

What analysts cover Biogen?

Biogen has been rated by Barclays, Morgan Stanley, Needham & Company LLC, Oppenheimer, SVB Leerink, Wedbush, and Wells Fargo in the past 90 days.

This page (NASDAQ:BIIB) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.